NCT00779935View on ClinicalTrials.gov

Growth Factor Concentration to Predict an Ankylosing Spondylitis Patient's Response to Infliximab (Study P04041)(COMPLETED)

PHASE4CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

October 1, 2004

Primary Completion Date

October 1, 2005

Study Completion Date

February 1, 2007

Conditions
Spondylitis, Ankylosing
Interventions
BIOLOGICAL

Remicade

Remicade will be given at Weeks 0, 2, and 6 and then every 8 weeks up to Week 54.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00779935 - Growth Factor Concentration to Predict an Ankylosing Spondylitis Patient's Response to Infliximab (Study P04041)(COMPLETED) | Biotech Hunter | Biotech Hunter